GENSCRIPT BIO

1548
30.4800.33% ( +0.100 )
Delay Closed: Nov 16, 16:08:11

Overview

GENSCRIPT BIO (1548)

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United S...

Open
30.380
High
30.680
Low
28.320
Prev. Close
30.380
Volume
37.34M
Turnover
1.11B
Avg Price
29.637
Bid/Ask Ratio
-43.86%
Amplitude
7.77%
52wk High
49.460
Volume Ratio
1.29
Turnover Ratio
1.63%
52wk Low
10.360
HK Mkt Cap
69.62B
Market CapHKD
69.62B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-2.19
EPSDynamic
-0.888
EPSStatic
--
BVPS
13.35
P/B
2.28
HK Shares
2.28B
Dividend YieldTTM
--
DividendTTM
--
Shares
2.28B
Min lot size
1,000
Currency
HKD

GENSCRIPT BIO Analyst Rating

View more

Forecast & Rating

Nov 2, 2026
Price forecast
HK$45.4449.07%
Forecast & RatingStrong buy
7analysts
  • Strong buy71.43%
  • Buy28.57%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    GenScript Biotech experienced a volatile session today, declining over 6% to HK$28.40 in the morning before staging a strong afternoon rebound, closing up 0.33% at HK$30.48. The morning selloff was driven by Q2 results—net loss jumped 407% year-over-year to HK$507 million, while revenue fell 22% to HK$1.59 billion. However, afternoon gains found support from new catalysts: JPMorgan noted the US nucleic acid screening rules are manageable, and Morgan Stanley highlighted accelerating China AI drug R&D financing that will boost wet lab demand, positioning the company as a beneficiary in the biotech outsourcing sector. GenScript is up 138% year-to-date but has pulled back 38% from its October high of HK$49.46, currently trading below its 20-day and 60-day moving averages, though the consensus analyst target remains above the current price, reflecting longer-term confidence in its AI and R&D outsourcing prospects.

  2. Nov, 13

    GenScript Biotech fell 4.58% to 30.38 HKD today, as the technical MACD death cross extended the pullback momentum. Q2 revenue of 15.85 billion HKD held sequentially flat but declined 22.15% year-over-year, while consecutive quarterly losses reached 5.07 billion HKD with a net margin of -31.99%. From a price standpoint, the stock has retreated 38.58% from its October peak of 49.46 HKD, yet remains up 137.53% year-to-date; currently trading well below both its 20-day moving average of 33.29 HKD and 60-day average of 36.06 HKD, signaling technical pressure. JPMorgan considers new nucleic acid screening regulations a manageable issue, while Morgan Stanley highlights that accelerating AI drug R&D financing in China should support wet lab service demand, providing some potential foundation for recovery.

  3. Nov, 12

    GenScript Biotech fell 6% to close at HK$31.84, pressured by a combination of broader Hong Kong market weakness (Hang Seng Index down 0.92%) and company-specific headwinds. The stock opened at HK$33.50 but retreated steadily through the morning session, peaking at HK$33.38 before surrendering those gains in the afternoon. The pullback caps a volatile week—the weekly recap noted a 15.04% decline—and reflects profit-taking from the stock's robust 148.94% year-to-date surge from HK$12.79. Adding to near-term uncertainty, JPMorgan flagged that new U.S. nucleic acid screening regulations pose operational challenges, though the bank characterized them as 'manageable.' Fundamentally, the company faces significant profitability headwinds: Q2 2026 delivered a net loss of HK$507.2 million on HK$1.59 billion in revenue (down 22% year-over-year), compounded by a deeply negative 31.99% net margin. Technically, the stock has slipped below both the 20-day moving average (HK$33.35) and 60-day moving average (HK$36.04), signaling momentum loss and now trading 35.62% below its October 5 high of HK$49.46. Morgan Stanley's recent positive commentary on China's AI drug R&D financing momentum offers a potential longer-term offset to near-term operating challenges.

  4. Nov, 11

    GenScript Biotech experienced significant intraday volatility, declining to an intraday low of HK$31.38 in the morning session before recovering to close at HK$34.74, up 2.72% from the previous close of HK$33.82, suggesting underlying support at lower levels. The stock has surged 171.62% year-to-date but remains 29.76% below its 52-week high of HK$49.46; the latest two quarters showed operating revenues declining 22.15% and 21.48% year-over-year, with Q2 net loss reaching HK$507 million. However, Morgan Stanley highlighted accelerating AI drug R&D financing in China driving demand for the company's wet lab services, while Huatai raised earnings forecasts and reiterated a buy rating, signaling analyst confidence in its AI-assisted drug discovery platform. The stock currently trades between its 20-day average (HK$33.50) and 60-day average (HK$36.00).

  5. Nov, 10

    GenScript Biotech surged approximately 8% to HK$33.82 today, reaching an intraday high of HK$34.94 in the morning session before retracing in afternoon trading. The gains are primarily supported by favorable industry tailwinds: Morgan Stanley notes that accelerating AI drug R&D financing in China should drive 'wet lab' demand growth, Huatai upgraded earnings forecasts with a reiterated buy rating, while JP Morgan assessed new nucleic acid screening rules as manageable. However, fundamental headwinds persist: revenues declined over 22% year-over-year in recent quarters, Q2 recorded a net loss of HK$507 million, and net profit margins remain deeply negative at -32%. Regarding valuation, the stock has surged 164% year-to-date but trades 31% below its 52-week high of HK$49.46 reached in early October, currently positioned between its 20-day and 60-day moving averages with a market capitalization of approximately HK$77.2 billion.

News